These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36028755)

  • 1. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
    Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
    Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
    Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
    Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome.
    Clough CA; Pangallo J; Sarchi M; Ilagan JO; North K; Bergantinos R; Stolla MC; Naru J; Nugent P; Kim E; Stirewalt DL; Subramaniam AR; Abdel-Wahab O; Abkowitz JL; Bradley RK; Doulatov S
    Blood; 2022 Mar; 139(13):2038-2049. PubMed ID: 34861039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
    Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
    Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
    Choi IY; Ling JP; Zhang J; Helmenstine E; Walter W; Tsakiroglou P; Bergman RE; Philippe C; Manley JL; Rouault-Pierre K; Li B; Wiseman DH; Batta K; Ouseph M; Bernard E; Dubner B; Li X; Haferlach T; Koget A; Fazal S; Jain T; Gocke CD; DeZern AE; Dalton WB
    Blood Adv; 2024 Aug; 8(15):3961-3971. PubMed ID: 38759096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
    Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
    Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
    Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
    Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
    Meng FK; Huang LF; Zhou JF; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
    Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
    Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
    Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
    Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biology of sideroblastic anemia].
    Harigae H
    Rinsho Ketsueki; 2017; 58(4):347-352. PubMed ID: 28484165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
    Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
    Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of
    Farrukh F; Abdelmagid M; Mangaonkar A; Patnaik M; Al-Kali A; Elliott MA; Begna KH; Hook CC; Hogan WJ; Pardanani A; Litzow MR; Ketterling RP; Gangat N; Arber DA; Orazi A; He R; Reichard K; Tefferi A
    Haematologica; 2024 Aug; 109(8):2525-2532. PubMed ID: 38450522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory anemia with ring sideroblasts.
    Malcovati L; Cazzola M
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.